Intelligene

Intelligene EBIT Margin

The EBIT Margin (Operating Margin) of Intelligene (7832.TWO) as of Oct 21, 2026 is -3,131.57 %. In the previous year, EBIT Margin (Operating Margin) was -1,147.44 % — a change of 172.92% (lower).

EBIT Margin

-3,131.57 %

YoY

172.92%

Last updated:

EBIT Margin (Operating Margin) of Intelligene is 2024 -3,131.57 % . EBIT Margin (Operating Margin) of Intelligene was 2023 -1,147.44 % . It decreases by 172.92% lower compared to the previous year.

For Intelligene, the operating (EBIT) margin of -3,131.6% is down versus -1,147.4% a few years ago.

The Intelligene EBIT Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT Margin
Date
EBIT Margin
Jan 1, 2023
-1,147.44 TWD
Jan 1, 2024
-3,131.57 TWD
The Intelligene EBIT Margin history
YEAREBIT MarginYoY
-3,131.57 %+172.92%
-1,147.44 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Intelligene Stock analysis

What does Intelligene do? Intelligene Inc develops innovative RNA gene therapy drugs using siRNA gene compilation technology for treating pneumonia and influenza. The company focuses on research and development of nucleic acid drugs targeting all cases of pneumonia and influenza. Intelligene Inc is a Taiwan-based company with 20 full-time employees operating in the pharmaceutical industry. The company's primary revenue comes from the development and potential commercialization of its RNA-based gene therapy drugs. Intelligene Inc is engaged in the research and development of innovative nucleic acid drugs based on siRNA technology for pneumonia and influenza treatments. The firm aims to provide novel therapeutic solutions for respiratory diseases through its proprietary technology. Intelligene Inc's products target medical professionals and healthcare institutions seeking advanced treatments for pneumonia and influenza. The company's research focuses on developing drugs that address all cases of these respiratory conditions. The firm operates within the pharmaceutical sector with a specific emphasis on RNA-based therapies for respiratory illnesses. Intelligene is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Intelligene stock

EBIT Margin (Operating Margin) of Intelligene is -3,131.57 % in 2024.

EBIT Margin (Operating Margin) of Intelligene changed from -1,147.44 % to -3,131.57 %, representing a 172.92% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBIT Margin (Operating Margin) Intelligene since 2006 – with annual values, charts, and detailed analysis.

EBIT Margin measures operating profitability as a percentage of revenue. It shows how much profit a company makes from operations before interest and taxes.

A 'good' varies by industry and company stage. On Eulerpool, you can compare EBIT Margin (Operating Margin)'s Intelligene with sector peers and the industry average to assess whether it is attractive.

To evaluate EBIT Margin (Operating Margin)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EBIT Margin (Operating Margin).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — Intelligene

All Key Metrics — Intelligene